Mediwound Ltd (MDWD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mediwound Ltd (MDWD) has a cash flow conversion efficiency ratio of -0.044x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.60 Million) by net assets ($59.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MDWD stock market capitalisation for the company's overall valuation and market capitalisation.
Mediwound Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Mediwound Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mediwound Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mediwound Ltd ranked by their cash flow conversion efficiency. Explore Mediwound Ltd (MDWD) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jarllytec Co Ltd
TWO:3548
|
0.017x |
|
Forte Biosciences Inc
NASDAQ:FBRX
|
-0.166x |
|
Vina San Pedro
SN:VSPT
|
0.001x |
|
TEN SQUARE GAMES SA
WAR:TEN
|
0.106x |
|
Shanghai Longyun Advg & Media
SHG:603729
|
0.031x |
|
Li Peng Enterprise Co Ltd
TW:1447
|
0.034x |
|
Intelligent Monitoring Group Ltd
AU:IMB
|
0.149x |
|
Ilshin Spinnin
KO:003200
|
0.005x |
Annual Cash Flow Conversion Efficiency for Mediwound Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Mediwound Ltd from 2012 to 2024. View MDWD stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $31.15 Million | $-13.62 Million | -0.437x | -32.03% |
| 2023-12-31 | $31.59 Million | $-10.46 Million | -0.331x | +69.58% |
| 2022-12-31 | $10.91 Million | $-11.88 Million | -1.089x | -155.96% |
| 2021-12-31 | $-4.58 Million | $-8.92 Million | 1.946x | +305.23% |
| 2020-12-31 | $7.27 Million | $-6.89 Million | -0.948x | -273.51% |
| 2019-12-31 | $15.17 Million | $8.29 Million | 0.546x | +140.34% |
| 2018-12-31 | $8.97 Million | $-12.15 Million | -1.355x | +20.80% |
| 2017-12-31 | $9.62 Million | $-16.45 Million | -1.710x | +19.18% |
| 2016-12-31 | $7.77 Million | $-16.45 Million | -2.116x | -153.42% |
| 2015-12-31 | $23.47 Million | $-19.60 Million | -0.835x | -117.08% |
| 2014-12-31 | $42.87 Million | $-16.49 Million | -0.385x | -178.22% |
| 2013-12-31 | $-19.80 Million | $-9.74 Million | 0.492x | +262.63% |
| 2012-12-31 | $15.63 Million | $-4.73 Million | -0.302x | -- |
About Mediwound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers an… Read more